Evoke Pharma, Inc.

Good afternoon, and welcome to the Evoque Pharma fourth quarter and full year 2024 earnings conference call. Currently, all callers have been placed in a listen-only mode, and following management's prepared remarks, the call will be opened for your questions. At that time, you may register to ask a question by pressing star and 1 on your telephone keypad. Please be advised that today's call is being recorded. We will be standing by if you should need any assistance. I would now like to turn the call over to Daniel Quinto-Boateng. Thank you, sir. You may begin.

Daniel Quinto- Good afternoon, and thank you for participating in Evoque Farmer's conference call today. With me today are Matt D'Onofrio, Evoque's Chief Executive Officer, Chris Questenberry, Jim Lodi's Chief Commercial Officer from Eversana, and Mark Kowieski, Evoque's Chief Financial Officer. By now, you should have a copy of the press release we issued earlier. If not, it is available on the investor relations page of our website at evokepharma.com. We encourage everyone to read today's press release as well as Evoke's annual report on Form 10-K, which is now filed with the SEC. The company's Form 10-K and earnings release are also available on Evoke's website. Please note that certain information discussed on the call today is covered under the Safe Harbor provisions the Private Securities Litigations Reform Act. We caution listeners that during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risk and certainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in the e-book's press releases and SEC filings. including its annual report on Form 10-K and subsequent filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Evoque undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With that, I would now like to turn the call over to Matt D'Onofrio. Matt?

Thank you, Daniel. Good afternoon, everyone. Thanks for joining today. I want to start with a patient story to keep our focus on why we're working so tirelessly to help persons suffering from gastroparesis. This quote here is from a real person, a patient that underscores why we do what we do at Evoke Pharma. A physician recently described to us a 23-year-old patient who had been to the ER eight times in the Uh, receiving our medication. He had lost his job and moved back in with his parents and he had dropped below a hundred pounds. He and his mother were desperate for a solution. One month after starting a Jumoti, he had not returned to the hospital. He had started regaining weight and he had only experienced one episode of vomiting when he missed a dose. That's the kind of life changing impact we aim to deliver. Stories like these drive us forward and reinforce our mission to make a meaningful difference in the lives of gastroparesis patients. 2024 was another growth year for Evoke Pharma. It was a year where we executed on our strategy, gained traction in the market, and delivered strong financial results. We achieved $10.2 million in total revenue, reflecting a 97% year-over-year increase, surpassing our prior $9.5 to $10 million guidance. In Q4 alone, we saw revenue of $3.3 million, a 24.6% sequential increase. A major driver of this growth was the expansion of Gemoti's prescriber base and improved prescription fulfillment. The transition to Aspen Pharmacies played a crucial role in this, significantly accelerating the delivery time of Gemoti and rapid adjudication of insurance authorizations for patients. This, along with our growing provider engagement, led to a 46% increase in prescribers year-over-year, bringing our total cumulative prescriber base to 2,553. Additionally, fill rates increased 72% year-over-year, and patient enrollments grew 22%. Our corporate position continues to improve with two additional Orange Book-listed patents that were allowed in 2024 and recently posted to the FDA website. We now have six listed patents related to Gemoti into 2030. Additionally, the recent Vanda CRL and FDA's posted notice on Domperidone discontinuation via the Compassionate Use Program further emphasize the critical need for Gemoti. Gemoti remains the only approved product to treat this disease that has any evidence of improvement over prior standard of care oral metoclopramide. We continue to capture stories of patients that are not adequately treated with oral medications and find relief with Gemoti, the only non-oral and reliable FDA-approved nasal treatment for gastroparesis. Evoque remains the only company positioned to elevate treatment for this devastating disease. Now we'll turn to Chris to recap our commercial progress over the course of 2024 and plans moving forward into 2025.